Audrey Sternberg | Authors

Articles

Responses After ASCT Were Extended With Daratumumab Maintenance and Standard Consolidation/Induction

June 21, 2021

The use of daratumumab as maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone was beneficial.

Prolonged Reponses Following ASCT and Standard Consolidation/Induction With Daratumumab Maintenance

June 20, 2021

Benefit was seen with daratumumab maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone.

Promising Responses Seen With Intensified Daratumumab Induction in Ultra High–Risk Multiple Myeloma

June 19, 2021

Intensified induction therapy with daratumumab plus cyclophosphamide, bortezomib, lenalidomide, and dexamethasone followed by bortezomib-augmented autologous stem cell transplant resulting in deep remissions or patients with ultra¬ high-risk multiple myeloma or primary plasma cell leukemia.